Optimer Pharma (OPTR) Will Get Milestone Payments from Specialised Therapeutics Australia for Fidaxomicin

Article Stock Quotes (1) Comments (0)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Specialised Therapeutics Australia Pty, Ltd. (STA) announced today the execution of an exclusive agreement to register and commercialize fidaxomicin tablets in Australia and New Zealand for the treatment of Clostridium difficile Infection (CDI).

Under the agreement Optimer is entitled to receive commercial milestone payments upon the achievement of cumulative net sales targets. In addition, Optimer will also receive payments for the supply of fidaxomicin tablets to STA for a return equivalent to approximately 30% of expected fidaxomicin sales in Australia and New Zealand. STA is responsible for all costs associated with the registration and commercialization of fidaxomicin tablets in Australia and New Zealand.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Men's Wearhouse (MW) Terminates George Zimmer; Postpones Annual Meeting
• Petrobras (PBR), SINOPEC (SNP) Enter Joint Development Agreement for Maranhão Refinery
• PetroQuest Energy (PQ) Acquires Gulf of Mexico Assets for $193M

Create E-mail Alert Related Categories

Corporate News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?